Amount of payment related to deferred cash consideration.

No definition available.

Name:	nhwk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPaymentOfDeferredCashConsideration
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of payment related to receivable contingent consideration.

+ References

No definition available.

+ Details

Name:	nhwk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPaymentOfReceivableContingentConsideration
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of contingent consideration paid arising out of acquisition.

+ References

No definition available.

+ Details

Name:	nhwk_PaymentOfContingentConsideration
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=nhwk_ElusysTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=nhwk_ContingentConsiderationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=nhwk_PelicanTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=nhwk_WarrantLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value of Financial Instruments - Change in Fair Value (Details) - USD ($)		9 Months Ended
	Apr. 18, 2022	Sep. 30, 2022	Sep. 30, 2021
Elusys Therapeutics
Change in fair value
Contingent consideration paid	$ 22,800,000
Contingent Consideration
Change in fair value
Balance at the beginning		$ 3,342,515
Change in fair value		(3,342,515)
Acquisition of Elusys		39,853,685
Payment of receivable consideration		(20,784,571)
Payment of deferred cash consideration		(2,000,000)
Balance at end		17,069,114
Contingent Consideration \| Pelican Therapeutics, Inc.
Change in fair value
Balance at the beginning		3,342,515	$ 2,912,515
Change in fair value		(3,342,515)	406,000
Balance at end			3,318,515
Contingent Consideration \| Elusys Therapeutics
Change in fair value
Acquisition of Elusys		39,853,685
Payment of receivable consideration		(20,784,571)
Payment of deferred cash consideration		(2,000,000)
Balance at end		17,069,114
Warrant Liability
Change in fair value
Balance at the beginning		11,020	33,779
Change in fair value		(10,746)	(2,808)
Balance at end		$ 274	$ 30,971